Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Thoracic 1Myeloid 1Lymphoid 1Classical hematology 1Breast 1

Conditions

Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Trastuzumab 696Paclitaxel 679Cyclophosphamide 634Docetaxel 554Capecitabine 468Letrozole 407Carboplatin 393Fulvestrant 379Doxorubicin 330Tamoxifen 288pembrolizumab 272Anastrozole 252Epirubicin 249exemestane 238pertuzumab 229Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 118

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Drug Screening Assays, Antitumor × Breast × Clear all
NCT00003253 2013-12-19

Evaluation of Drug Resistance in Patients With Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
100 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡